Business
Sierra Oncology Granted US and EU Patents
Sierra Oncology Granted US and EU Patents.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6039G Sareum Holdings PLC 31 May 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n31 May 2017\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nSierra Oncology Granted US and EU Patents for Chk1 inhibitor SRA737 \nSareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, notes an announcement made by Sierra Oncology, Inc. yesterday stating that selection patents* that explicitly protect the Chk1 inhibitor SRA737 have been granted in the USA and Europe, extending its protection period to the year 2033 in the US.\nThe full announcement can be found on Sierra Oncology's IR website**.\nDr Tim Mitchell, CEO of Sareum, commented: \"SRA737 is a valuable asset to Sareum through its licence to Sierra Oncology. We are pleased to see that patents to protect it have been granted in these major territories.\"\nSierra Oncology holds exclusive and worldwide rights for the Chk1 inhibitor, SRA737, having licensed the programme from Sareum's co-investment partner, the CRT Pioneer Fund in September 2016. This announcement does not trigger any milestone payments under the terms of the agreement.\n* Patent nos US 9,663,503, EU 2855448\n**http://investor.sierraoncology.com/2017-05-30-Sierra-Oncology-Granted-US-and-EU-Patents-for-Chk1-inhibitor-SRA737\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / Nick Prowting\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nThe Communications Portfolio (Sareum Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\nNotes for editors: \nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in Septembe...